Clinically Proven Medical Weight-Loss Options
A comprehensive comparison of traditional diet pills, GLP-1 injections, new oral medicines, nutrition treatment and procedures—and how W8MD physicians help patients choose safely.
Obesity is a chronic disease influenced by genetics, appetite regulation, environment, medications, sleep, metabolic health and behavior. It is not evidence of weak character. At the same time, claims that insulin resistance, carbohydrates or any single hormone explain every case are too simplistic. Weight increases when energy stored over time exceeds energy used, but the biological and social factors governing hunger, intake and expenditure vary substantially among individuals.
A useful medical evaluation looks at BMI and waist size while also reviewing blood pressure, glucose, lipids, liver health, medications, menstrual history, sleep, eating behavior and previous treatment. Learn more from W8MD’s guides to causes of weight gain, insulin resistance and sleep apnea and weight loss.
Who may qualify for prescription treatment?
Many chronic weight-management medications are indicated for adults with a BMI of at least 30, or a BMI of at least 27 with a weight-related condition such as hypertension, dyslipidemia, type 2 diabetes or obstructive sleep apnea. The exact criteria, age range and contraindications differ by product. BMI is a screening tool rather than a complete diagnosis, and prescription eligibility requires an individualized clinical assessment.
Complete overview of medical weight-loss treatments
| Treatment | How it works | Potential advantages | Important considerations |
|---|---|---|---|
| Phentermine | Sympathomimetic appetite suppressant approved for short-term use. | Oral, inexpensive and familiar; may reduce hunger quickly. | Can raise pulse or blood pressure and cause insomnia, dry mouth or anxiety. Not appropriate in pregnancy or for some cardiovascular, thyroid, glaucoma or substance-use histories. |
| Phentermine/topiramate ER (Qsymia) | Combines appetite suppression with topiramate’s effects on satiety and cravings. | Among the more effective established oral options; once-daily brand formulation. | Major pregnancy-related birth-defect risk; requires contraception and pregnancy precautions when applicable. Mood, cognitive, heart-rate and eye-related risks require review. Generic separate-tablet prescribing is not identical to Qsymia’s formulation or dosing. |
| Naltrexone/bupropion ER (Contrave) | Acts on appetite and reward pathways. | Oral; may be useful when cravings or reward-driven eating are prominent. | Not for patients using opioids or with uncontrolled hypertension, seizure disorders or certain eating disorders. Carries bupropion-related warnings. |
| Orlistat (Xenical; lower-dose Alli OTC) | Reduces absorption of dietary fat in the intestine. | Non-systemic mechanism; an over-the-counter strength exists. | Oily stools, urgency and fat-soluble vitamin deficiency can occur; diet composition and medication interactions matter. |
| Liraglutide (Saxenda) | Daily injectable GLP-1 receptor agonist that reduces appetite and increases fullness. | Established chronic weight-management option, including certain adolescents. | Daily injections and gastrointestinal effects; generally less average weight loss than newer weekly incretin treatments. |
| Wegovy injection (semaglutide) | Weekly GLP-1 receptor agonist affecting appetite, satiety and calorie intake. | Substantial average weight loss; also has cardiovascular and other specific indications in eligible populations. | Gradual dose escalation; nausea, vomiting, diarrhea or constipation may occur. Product-specific contraindications and warnings must be reviewed. |
| Wegovy tablets (oral semaglutide) | Once-daily oral GLP-1 treatment approved for chronic weight management. | FDA-approved non-injectable semaglutide option for selected patients. | Administration instructions, interactions, gastrointestinal effects, adherence and coverage differ from injections. It is not interchangeable dose-for-dose with other semaglutide products. |
| Wegovy HD 7.2 mg | Higher-dose weekly semaglutide injection approved in 2026 for eligible adults. | Additional semaglutide option with potential for greater weight reduction in selected adults. | Not a starting dose and not suitable for everyone; requires escalation, tolerance assessment and product-specific prescribing. |
| Zepbound (tirzepatide) | Weekly dual GIP/GLP-1 receptor agonist that reduces appetite and calorie intake. | Produced the greatest average weight reductions among widely used approved weekly injections in separate pivotal trials; also approved for moderate-to-severe OSA in selected adults with obesity. | Gastrointestinal effects, dose escalation, contraindications and cost require review. Cross-trial comparisons are not the same as head-to-head evidence. |
| Foundayo (orforglipron) | Once-daily oral, nonpeptide GLP-1 receptor agonist approved in 2026. | New FDA-approved oral option that does not require an injection. | Newer product with its own escalation, boxed warning, contraindications, side-effect profile, availability and coverage considerations. |
| Setmelanotide (Imcivree) | Melanocortin-4 receptor agonist. | Can be effective for specific confirmed rare genetic obesity syndromes. | Not a general obesity medication; requires precise genetic or syndrome-based eligibility. |
| Other short-term sympathomimetics Diethylpropion, phendimetrazine, benzphetamine |
Appetite suppressants approved for short-term treatment. | Oral and sometimes lower cost. | Stimulant-type adverse effects, controlled-substance status and limited long-term evidence; used less commonly than phentermine. |
How much weight can medications produce?
Results vary with dose, duration, adherence, baseline health, nutrition, activity and whether treatment is continued. In trials, older oral agents generally produced modest-to-moderate average loss, phentermine/topiramate produced larger average loss than many older pills, semaglutide produced substantial average loss, and tirzepatide produced still larger average reductions in separate pivotal programs. These are population averages—not guarantees for an individual—and comparisons across different trials can be misleading.
Diabetes brands, obesity brands and compounded products
Semaglutide names
Wegovy carries chronic weight-management indications. Ozempic and Rybelsus are semaglutide products primarily approved for type 2 diabetes-related indications. They are not interchangeable with Wegovy solely because they share an active ingredient.
Tirzepatide names
Zepbound is the tirzepatide obesity and OSA brand. Mounjaro is the type 2 diabetes brand. Exact product, indication and dose must be identified.
Compounded semaglutide or tirzepatide is not FDA-approved, is not a generic version of Wegovy or Zepbound, and does not undergo FDA premarket review for safety, effectiveness or quality. FDA-approved products should be used when they meet the patient’s medical needs and are accessible. Patients considering any compounded medication should discuss why it is being proposed, the pharmacy, the exact active ingredient, dosing units, storage and risks with a licensed clinician.
Traditional pills remain useful
Newer incretin drugs often achieve greater average weight loss, but an injection or newer brand is not automatically the best choice. Phentermine/topiramate remains one of the most effective oral strategies for appropriately selected patients and may offer predictable, lower program costs. Phentermine alone may be helpful when short-term appetite reduction is clinically appropriate. Contrave may fit a different eating pattern, while orlistat uses a non-stimulant intestinal mechanism.
The correct comparison includes blood pressure, heart history, psychiatric and seizure history, opioid use, pregnancy potential, glaucoma, thyroid disease, gastrointestinal tolerance, kidney or liver health, cost and the patient’s preference for pills versus injections.
Nutrition, activity, sleep and behavioral treatment
Medication is an adjunct—not a substitute for comprehensive care. A sustainable plan generally includes adequate protein, fiber-rich foods, hydration, a manageable calorie deficit, resistance activity, aerobic movement, sleep and strategies for cravings or emotional eating. Exercise alone often causes only modest scale loss, but it improves fitness, preserves lean mass, reduces health risks and supports maintenance.
Sleep deserves specific attention. Obstructive sleep apnea can fragment sleep and worsen daytime fatigue and cardiometabolic risk. W8MD integrates sleep evaluation and may offer home sleep testing for appropriate patients. Read more about why sleep apnea matters for weight loss.
Procedural treatment
Metabolic and bariatric surgery
Sleeve gastrectomy and gastric bypass can produce substantial and durable weight loss and improve metabolic disease in appropriately selected patients. They require surgical evaluation, nutritional supplementation and lifelong follow-up.
Endoscopic procedures
Endoscopic sleeve gastroplasty and intragastric balloons may be considered for selected patients. Availability, eligibility, average results, reversibility, adverse effects and insurance coverage differ.
What is still investigational?
Retatrutide, CagriSema, MariTide and several other next-generation agents have generated promising clinical-trial data, but they should not be presented as FDA-approved weight-loss treatments unless and until the FDA approves a specific product and indication. Patients should be cautious about clinics selling “research use only” peptides. Clinical trials differ from commercial prescribing.
Physician-supervised programs with transparent starting prices
Medical evaluation required. Eligibility, dose, medication source, pharmacy, availability, visit coverage and total cost vary. GLP-1 prices may increase with dosage. Insurance acceptance for visits does not guarantee medication coverage. Compounded medications are not FDA-approved or generic equivalents of approved brands.
How W8MD physicians help choose the right option
With more than 20 years of clinical experience, W8MD Weight Loss, Sleep and MedSpa physicians help patients in greater New York City, New Jersey, Philadelphia and nearby areas compare benefits, risks and cost instead of promoting one product to everyone.
- Review BMI, waist size, weight history and previous treatment.
- Assess blood pressure, metabolic risk, current medications and contraindications.
- Screen for PCOS, prediabetes, fatty liver and sleep apnea when appropriate.
- Compare oral medicines, injections, new tablets and non-medication care.
- Develop protein, hydration, nutrition and physical-activity goals.
- Monitor adverse effects, response and dose decisions.
- Assist with insurance prior authorization when a covered benefit exists.
- Plan for long-term maintenance and early management of regain.
“Fantastic program. Truly a life changer!”
D.M. — W8MD patient success story
D.M. reported losing 100 pounds and maintaining the loss for more than ten years. Individual results vary; this experience does not predict another patient’s outcome.
W8MD locations
Brooklyn, New York
2632 East 21st Street, Suite L3
Brooklyn, NY 11235
Serving Brooklyn, Manhattan, Queens, Staten Island, the Bronx, Long Island, New Jersey and greater NYC.
NYC medical weight loss by W8MDNortheast Philadelphia
1718 Welsh Road, 2nd Floor, Suite C
Philadelphia, PA 19115
Serving Philadelphia, Pennsylvania, South Jersey and Delaware communities.
Philadelphia medical weight loss by W8MDFrequently asked questions
What is the most effective FDA-approved weight-loss medication?
In separate pivotal trials, tirzepatide produced the largest average weight reductions among commonly used approved injections, while semaglutide and phentermine/topiramate also produced substantial average reductions. A cross-trial ranking cannot determine which treatment is best for an individual. Health history, contraindications, side effects, access and cost matter.
What is the most affordable prescription option?
Generic phentermine or a medically appropriate phentermine/topiramate strategy may cost less than branded incretin products. W8MD also offers semaglutide- and tirzepatide-based starting-price pathways. Total cost must include visits, dose changes, laboratory work, shipping and medication source.
Are there FDA-approved weight-loss pills?
Yes. Oral choices include phentermine, phentermine/topiramate ER, naltrexone/bupropion ER, orlistat, Wegovy tablets and Foundayo/orforglipron. Short-term agents such as diethylpropion and phendimetrazine also exist. Each has distinct indications and risks.
Can I take phentermine with a GLP-1 medication?
Combination prescribing may be considered by some clinicians, but it is not automatically appropriate and may be off-label. Evidence, blood pressure, pulse, side effects, interactions and total appetite suppression must be reviewed. Never combine prescriptions without the treating clinician’s direction.
Do GLP-1 medications permanently cure obesity?
No. They treat a chronic condition while taken. Weight regain is common after stopping effective therapy, so duration, affordability and maintenance planning should be discussed before starting.
Does insurance cover weight-loss medication?
Coverage varies widely. A plan may cover physician visits but exclude anti-obesity drugs. Approval can depend on BMI, related conditions, formulary rules and previous treatment. W8MD can help submit prior authorization when coverage exists and criteria are met, but approval is not guaranteed.
Are compounded GLP-1 medicines the same as Wegovy or Zepbound?
No. Compounded medications are not FDA-approved and are not generic equivalents of Wegovy or Zepbound. FDA has warned about dosing errors and fraudulent products. The medication source and reason for compounding should be discussed explicitly.
Can weight-loss medication be used during pregnancy?
Weight-loss medications are generally not used for weight reduction during pregnancy, and some—especially topiramate-containing treatment—have major fetal risks. Pregnancy plans, contraception and product-specific discontinuation guidance require clinician review.
Related W8MD articles
WikiMD encyclopedia resources
Authoritative updates
- FDA: Foundayo/orforglipron approval
- FDA: higher-dose Wegovy approval
- FDA: Zepbound approval for chronic weight management
- FDA concerns about unapproved GLP-1 products
